# Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension

> **NCT01070030** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 230 (actual)

## Conditions studied

- Stage II Hypertension

## Interventions

- **DRUG:** Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)

## Key facts

- **NCT ID:** NCT01070030
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01070030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01070030, "Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01070030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*